Similarly, novel pharmacological agents such as NMDA receptor antagonists for GRIN2A/GRIN2B mutations, KCNQ channel openers for KCNQ2-related epileptic encephalopathies, and IGF-1 analogues for trophic deficiency syndromes signify the forthcoming generation of personalized treatments. This evidence concerns the gene GRIN2A and Epileptic encephalopathy.